Cytori Reports Q2 2018 Business and Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Maxim Group Downgrades Cytori Therapeutics, Inc. (CYTX) to Hold
August 15, 2018 7:40 AM EDTMaxim Group analyst Jason McCarthy downgraded Cytori Therapeutics, Inc. (NASDAQ: CYTX) from Buy to Hold and removes their price target.
McCarthy said their fundamental view around the company's key programs of 0918 (liposomal doxorubicin) and cell therapy (scleroderma, stress urinary incontinence) are unchanged, but... More
Cytori Therapeutics, Inc. (CYTX) PT Lowered to $5 at H.C. Wainwright on Rising Share Count
August 15, 2018 7:12 AM EDTH.C. Wainwright analyst Jason Kolbert lowered the price target on Cytori Therapeutics, Inc. (NASDAQ: CYTX) to $5.00 (from $6.00) while maintaining a Buy rating.
Kolbert notes while catalysts lay ahead they are lowering the price target on a rising share... More
Cytori Therapeutics (CYTX) Misses Q2 EPS by 14c
August 14, 2018 4:23 PM EDTCytori Therapeutics (NASDAQ: CYTX) reported Q2 EPS of ($0.59), $0.14 worse than the analyst estimate of ($0.45).
For earnings history and earnings-related data on Cytori Therapeutics (CYTX) click here.
... More